Board of Directors

Carl Goldfischer is an Investment Partner and Managing Director of Bay City Capital, serving as a member of the board of directors and executive committee, and has been with the firm since December 2000. His background includes extensive public and private investment and transaction work, as well as clinical trial development knowledge. Prior to joining Bay City Capital, Carl was, until mid-2000, Chief Financial Officer of ImClone Systems where he oversaw financial operations and strategic planning. Carl serves on the board of directors of numerous companies, including: BrainCells, EnteroMedics, Epizyme and Metabolex. He received an MD with honors in Scientific Research from Albert Einstein College of Medicine, and a BA from Sarah Lawrence College.

Dr. Jayson Dallas served as President and Chief Executive Officer of Aimmune Therapeutics, Inc., a biopharmaceutical company developing treatments for potentially life-threatening food allergies, from June 2018 until its acquisition by Sociétés des Produits Nestlé, S.A., in October 2020. Prior to joining Aimmune, he served as the first Chief Commercial Officer and Executive Vice President of Ultragenyx Pharmaceutical, Inc., a publicly held biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, since August 2015. Prior to Ultragenyx, Jayson served as General Manager of Roche, a healthcare company, in the United Kingdom from January 2013 to July 2015. Before joining Roche, he held two different positions at Genentech, a pharmaceutical company, as Head of Global Oncology Launch Excellence and Biosimilar Strategy and Head of Global Product Strategy for Immunology and Ophthalmology, from May 2010 to December 2012 in South San Francisco. Earlier in his career, Dr. Dallas worked at Novartis and Pfizer / Pharmacia in the United States and previously at Roche in Switzerland. Dr. Dallas is the Executive Chairman of Rivus Pharmaceuticals and also serves on the board of directors of Arena Pharmaceuticals, Inc. (NASDAQ: ARNA). Dr. Dallas holds an M.D. from the University of the Witwatersrand, Johannesburg, South Africa and an M.B.A. from Ashridge Business School in the United Kingdom.

Chau Q. Khuong is a biotech entrepreneur and venture capital investor. From 2003 until 2021, he worked at OrbiMed Advisors, a global healthcare-dedicated investment firm with over $15 billion in assets under management. At the time of his retirement from OrbiMed, Chau was Partner and member of the investment committee for the OrbiMed venture capital funds.  Over the past two decades, he was an active lead investor in innovative drug development and medical device enterprises across all stages and therapeutic areas including oncology, infectious diseases, ophthalmology, gene therapy and gene editing. Chau has served in a Board of Directors capacity of numerous public and private companies, including Arius Research (acquired by Roche), Durata (acquired by Actavis), Glaukos Medical (NYSE: GKOS), Intellia Pharmaceuticals (NASDAQ: NTLA), Intercept Pharmaceuticals (NASDAQ: ICPT), Inspire Medical Systems (NYSE: INSP). He holds a BS in molecular, cellular and developmental biology with a concentration in biotechnology and an MPH with a concentration in infectious diseases, both from Yale University.

Søren Møller joined Novo A/S in 2011 as Managing Investment Director of Novo Seeds. Søren obtained his MSc degree from the Technical University of Denmark in 1993 and his PhD degree in molecular biology in 1997 from the Technical University of Denmark. In addition, Søren has academic training as postdoctoral fellow at Stanford University School of Medicine. Prior to joining Novo Seeds, Søren served as global manager of Genomics at Novozymes. Before Novozymes, Søren was CSO and Vice President of R&D at Exiqon A/S. During Søren’s tenure, Exiqon completed an IPO and the company was acquired by Qiagen in 2016. Previously, Søren worked in cancer drug development as head of Lead Identification at BioImage and as research scientist at Novo Nordisk.

Amit D. Munshi is Director, President and Chief Executive Officer of San Diego based Arena Pharma since May 2016. Previously, Amit served as President and Chief Executive Officer of Epirus Biopharmaceuticals, Inc. and Percivia LLC, a biotechnology company (sold to JNJ). Prior to Epirus and Percivia, he was a co-founder and served as Chief Business Officer of Kythera Biopharmaceuticals, Inc., from 2005 to 2010, (sold $2.1B to AGN) and held multiple leadership positions at Amgen Inc. from 1997 to 2005, including General Manager, Nephrology Europe. Amit holds a B.S. in Economics and a B.A. in History from the University of California, Riverside, and an M.B.A. from the Peter F. Drucker School of Management at Claremont Graduate University. He has more than 30 years of global biopharmaceutical industry experience in executive management, business development, product development and portfolio management. Amit currently serves on the boards of Pulmatrix, Inc. (Nasdaq: PULM) and Enterprise Therapeutics Ltd, and also serves as an advisor and lecturer at the Peter F. Drucker School of Management at the Claremont Graduate School.

Anne Prener has more than 25 years of leadership experience within life sciences companies, and currently serves as Chief Executive Officer of Imbria Inc. and as venture partner at SV Health Investors. Anne previously served as CEO of Freeline Ltd. Anne has led companies and teams across several therapeutic areas, including a focus on rare diseases. As CEO of Freeline, a liver-directed gene therapy company, she scaled the company from preclinical stage to a fully integrated biotechnology organization, which included a broad, internally developed pipeline, two programs in clinical development and a commercial-scale, high-quality CMC and manufacturing platform. Prior to joining Freeline, she served as CEO of Gyroscope Therapeutics Ltd., a gene therapy company focused on eye diseases. Before that, Anne was Global Therapeutic Area Head of Hematology and Vice President, Clinical Research Hematology at Baxalta. During her time there, three new major product approvals in the U.S. and EU were secured along with a significant advancement in Baxalta’s hematology portfolio. Earlier in her career, Anne held several positions of increasing responsibility at Novo Nordisk, most recently serving as Senior Vice President, Hemophilia R&D Portfolio, where she was instrumental in building a portfolio of late stage and commercial hemophilia products. Anne serves on the Boards of Directors of several life science companies, Rubius Therapeutics, Kaleido Bioscience and Renovacor. Anne holds a Ph.D. in epidemiology and an M.D., both from the University of Copenhagen.

Hans Schambye is a seasoned biotech entrepreneur with extensive experience in drug discovery and development. Previously, Hans served as the Chief Executive Officer of ReceptIcon from 2006 to 2009 and as the CEO of Gastrotech Pharma A/S from 2004 to 2006. Before joining Gastrotech, he was Director of Biology and Pharmacology and Head of Portfolio Management at Maxygen, a US biotech company. Hans has co-founded several biotech companies, including ProFound Pharma A/S, a Danish biotech company, which was acquired by Maxygen in 2000. Prior to this he had a successful research career at Stanford University and Copenhagen University within the field of receptor biology. Hans holds an MD from Odense University and a PhD in Medical Sciences from Copenhagen University.

David Shapiro has considerable experience in drug development and was Chief Medical Officer and head of R&D at Intercept Pharmaceuticals from 2007 until 2019 where he led the development of obeticholic acid. This program culminated in the drug’s approval for the treatment of primary biliary cholangitis and the first successful Phase 3 study and regulatory filing for nonalcoholic steatohepatitis (NASH), the most prevalent liver disease in the developed world. Prior to this, he was CMO at Idun Pharmaceuticals which was acquired by Pfizer in 2005. David served as President of the Scripps Medical Research Center at Scripps Clinic and held senior appointments at several biotechnology companies. Prior to joining the biotech sector, he led Merck’s highly competitive hypertension clinical research program. David received his medical degree from Dundee University and undertook post-graduate training in general and respiratory medicine in Oxford and the University of Vermont. He is both a Fellow of the Royal College of Physicians of London and a Fellow of the College’s Faculty of Pharmaceutical Medicine. David has lectured and organized numerous symposia on improving the drug development process and served twice on the Executive Committee of the American Academy of Pharmaceutical Physicians and in 2015-2017 was Co-Chairman of the interdisciplinary Liver Forum, a group of academic, industry and regulatory members focused on speeding the pathway for new therapeutics in NASH.